Effects of Colesevelam Hydrochloride (WelChol) on Biomarkers of Inflammation in Patients With Mild Hypercholesterolemia

American Journal of Cardiology

Volumn 98, Issue 5, 2006, Pages 641-643

  Devaraj, Sridevi ^a   Autret, Bryce ^a   Jialal, Ishwarlal ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COLESEVELAM; LOW DENSITY LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ALLYLAMINE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; TREATMENT OUTCOME;

EID: 33747160207     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.03.043     Document Type: Article

References (14)

1. Jialal I., and Devaraj S. Inflammation and atherosclerosis. the value of the high-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol 116 suppl (2001) S108-S115
2. Rifai N., and Ridker P.M. High-sensitivity C-reactive protein. a novel and promising marker of coronary heart disease. Clin Chem 47 (2001) 403-411
3. Insull Jr. W., Toth P., Mullican W., Hunninghake D., Burke S., Donovan J.M., and Davidson M.H. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia. a 24-week randomized controlled trial. Mayo Clin Proc 76 (2001) 971-982
4. Davidson M.H., Dillon M.A., Gordon B., Jones P., Samuels J., Weiss S., Isaacsohn J., Toth P., and Burke S.K. Colesevelam hydrochloride (Cholestagel). a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 159 (1999) 1893-1900
5. Knapp H.H., Schrott H., Ma P., Knopp R., Chin B., Gaziano J.M., Donovan J.M., Burke S.K., and Davidson M.H. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 110 (2001) 352-360
6. Davidson M.H., Toth P., Weiss S., McKenney J., Hunninghake D., Isaacsohn J., Donovan J.M., and Burke S.K. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 24 (2001) 467-474
7. Hunninghake D., Insull Jr. W., Toth P., Davidson D., Donovan J.M., and Burke S.K. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 158 (2001) 407-416
8. McKenney J., Jones M., and Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin 21 (2005) 1403-1412
9. Devaraj S., and Jialal I. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radic Biol Med 29 (2000) 790-792
10. Devaraj S., and Jialal I. Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications. the effect of alpha-tocopherol supplementation. Circulation 102 (2000) 191-196
11. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., and Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 (2001) 1933-1935
12. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., Gotto Jr. A.M., and Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
13. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
14. Ballantyne C.M., Houri J., Notarbartolo A., Melani L., Lipka L.J., Suresh R., Sun S., LeBeaut A.P., Sager P.T., Veltri E.P., and Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. a prospective, randomized, double-blind trial. Circulation 107 (2003) 2409-2412